Currently predicting for Mon, 1 Apr 2024

Trading levels for ABIO

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 1.79 1.92 %
R2 1.78 1.06 %
R1 1.77 0.530 %
Current price: 1.76
Support S1 1.74 -1.18 %
S2 1.73 -1.71 %
S3 1.71 -2.57 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 0 .
R2 1.78 1.14 %
R1 1.77 0.568 %
Current price 1.76
Support S1 1.70 -3.41%
S2 1.65 -6.25%
S3 1.64 -6.82%

ABIO Predictions History

3 years ago
JS predicted that ABIO for 2020-05-11 is going $4.04 (1.51%)

3 years ago
MacSteele13 predicted that ABIO for 2020-05-11 is going

Rank:

4 years ago
JS predicted that ABIO for 2019-06-27 is going $6.27 (-11.32%)

4 years ago
JS predicted that ABIO for 2019-05-17 is going $8.73 (-7.23%)

4 years ago
JS predicted that ABIO for 2019-05-08 is going $13.23 (-12.38%)

4 years ago
PumpTheseNumbers predicted that ABIO for 2019-05-08 is going $12.02 (-20.40%)

4 years ago
joe1234 predicted that ABIO for 2019-05-08 is going $13.00 (-13.91%)

4 years ago
Alex.TinyVillianaire.Goh.110165 predicted that ABIO for 2019-05-08 is going $9.55 (-24.09%)

Rank:

4 years ago
GoldenNugget predicted that ABIO for 2019-05-07 is going $10.73 (-5.69%)

4 years ago
NameNotImportant predicted that ABIO for 2019-05-03 is going $10.14 (-6.97%)

Click to get the best stock tips daily for free!

About ARCA biopharma

ARCA biopharma ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase... ABIO Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT